Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. Our transformative product candidates are – best in class – Adoptive Cell Therapies and Bispecific TCR molecules. These products are directed against tumor targets that have been identified and validated by Immatics’ proprietary and world-leading XPRESIDENT® technology. Our mission is to bring the power of T-cell redirecting immunotherapies to cancer patients.
Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior targeted conditioning prior to a bone marrow transplant and adoptive cell therapy The Company’s targeted Antibody Radio-Conjugates (ARCs), combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. Actinium is developing a pipeline of clinical-stage ARCs targeting CD45 and CD33 for patients with a broad range of hematologic malignancies.
Noile-Immune Biotech is a Tokyo-based clinical stage biotechnology company focused on the development of next generation CAR-T cells for solid tumors. Our proprietary Prime (Proliferation-inducing and migration-enhancing) CAR-T technology which express particular combination of IL-7 and CCL19, is designed to enhance anti-tumor potential by enabling infiltration, accumulation, and survival of CAR-T cells in coordination with activation of tumor-reactive host T cells and their memory formation. Read more here.
Diamond Pharma Services is a leading European technical and scientific consulting group with deep expertise in gene therapies. Diamond are proud to have supported the regulatory approval of the first gene therapy product in Europe (Glybera), and continue to work on a broad portfolio of gene, and gene modified cell therapies. Diamond offers a comprehensive service including regulatory affairs, product development (non-clinical, CMC and clinical), pharmacovigilance and quality & compliance.